Autonomous B-cell Receptor Signaling in Chronic Lymphocytic Leukemia.

IF 2.7 3区医学 Q2 HEMATOLOGY

Hematology-Oncology Clinics of North America Pub Date : 2025-07-16 DOI:10.1016/j.hoc.2025.05.004

Anastasia Iatrou, Andreas Agathangelidis, Jessica Bordini, Kostas Stamatopoulos, Paolo Ghia

引用次数: 0

Abstract

Chronic lymphocytic leukemia (CLL) is driven by both antigen-dependent and antigen-independent cell-autonomous B-cell receptor (BcR) signaling. The latter has been documented in CLL cases in different disease subgroups and correlates with disease progression. Autonomous signaling is also relevant in monoclonal B-cell lymphocytosis and other B-cell malignancies, including diffuse large B-cell lymphoma and splenic marginal zone lymphoma. This article examines its molecular basis, prognostic significance, and potential therapeutic relevance, highlighting the need for novel strategies to overcome resistance and improve outcomes.

查看原文本刊更多论文

慢性淋巴细胞白血病的自主b细胞受体信号传导。

慢性淋巴细胞白血病（CLL）是由抗原依赖性和抗原非依赖性细胞自主b细胞受体（BcR）信号驱动的。后者已在不同疾病亚组的CLL病例中得到证实，并与疾病进展相关。自主信号也与单克隆b细胞淋巴细胞增多症和其他b细胞恶性肿瘤有关，包括弥漫性大b细胞淋巴瘤和脾边缘区淋巴瘤。本文探讨其分子基础，预后意义和潜在的治疗相关性，强调需要新的策略来克服耐药性和改善结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology-Oncology Clinics of North America 医学-血液学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more.